Data shows new Roche leukemia drug may improve on Rituxan

May 15, 2013 10:27 PM

12 0

Data shows new Roche leukemia drug may improve on Rituxan

(Reuters) - An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as long as chemotherapy, according to preliminary trial data released on Wednesday.

Switzerland-based Roche aims to fend off cheaper competition for Rituxan, which loses patent protection in Europe later this year, threatening a product with nearly $7 billion in annual sales.

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...